HLS vs. ACB, TLRY, WEED, FIRE, EPI, ICC, OGI, CPH, RIV, and LEAF
Should you be buying HLS Therapeutics stock or one of its competitors? The main competitors of HLS Therapeutics include Aurora Cannabis (ACB), Tilray Brands (TLRY), Canopy Growth (WEED), Supreme Cannabis (FIRE), ESSA Pharma (EPI), ICC Labs (ICC), Organigram (OGI), Cipher Pharmaceuticals (CPH), RIV Capital (RIV), and Leaf Mobile (LEAF). These companies are all part of the "drug manufacturers - specialty & generic" industry.
HLS Therapeutics vs. Its Competitors
Aurora Cannabis (TSE:ACB) and HLS Therapeutics (TSE:HLS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.
HLS Therapeutics has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than HLS Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aurora Cannabis has a beta of 2.71, meaning that its share price is 171% more volatile than the S&P 500. Comparatively, HLS Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.
Aurora Cannabis received 497 more outperform votes than HLS Therapeutics when rated by MarketBeat users. However, 64.15% of users gave HLS Therapeutics an outperform vote while only 63.14% of users gave Aurora Cannabis an outperform vote.
13.4% of Aurora Cannabis shares are held by institutional investors. Comparatively, 65.2% of HLS Therapeutics shares are held by institutional investors. 0.4% of HLS Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Aurora Cannabis currently has a consensus target price of C$8.75, indicating a potential upside of 5.68%. HLS Therapeutics has a consensus target price of C$4.50, indicating a potential downside of 9.09%. Given Aurora Cannabis' stronger consensus rating and higher probable upside, analysts plainly believe Aurora Cannabis is more favorable than HLS Therapeutics.
In the previous week, Aurora Cannabis had 1 more articles in the media than HLS Therapeutics. MarketBeat recorded 1 mentions for Aurora Cannabis and 0 mentions for HLS Therapeutics. Aurora Cannabis' average media sentiment score of 0.75 beat HLS Therapeutics' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.
Aurora Cannabis has a net margin of -22.55% compared to HLS Therapeutics' net margin of -38.70%. Aurora Cannabis' return on equity of -8.36% beat HLS Therapeutics' return on equity.
Summary
Aurora Cannabis beats HLS Therapeutics on 12 of the 18 factors compared between the two stocks.
Get HLS Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HLS Therapeutics Competitors List
Related Companies and Tools
This page (TSE:HLS) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy HLS Stock Free HLS Stock Alerts